Table 1.
Currently Approved Biological DMARDs and Targeted Agents
| Target | English Generic Name | Type | Approved on USA |
|---|---|---|---|
| TNF-α | Infliximab | Human-mouse chimeric IgG1 antibody | 1999 |
| Etanercept | TNF-α receptor IgG1 Fc fusion protein | 1998 | |
| Adalimumab | Fully human IgG1 antibody | 2003 | |
| Golimumab | Humanized IgG1 antibody | 2009 | |
| Certolizumab Pegol | PEG modified anti-TNF-α antibody Fab fragment | 2009 | |
| IL-1 | Anakinra | IL-1 receptor antagonist | 2003 |
| IL-6 | Tocilizumab | Humanized IgG1 antibody | 2010 |
| Sirukumab | Fully human antibody | 2017 | |
| CD20 | Rituximab | Human-mouse chimeric IgG1 antibody | 2006 |
| BLyS | Belimumab | Fully human IgG1 antibody | 2011 |
| CTLA-4 | Abatacept | CTLA-4 antigen extracellular region-Fc fusion protein | 2006 |
| JAK1, JAK2, JAK3 | Tofacitinib | Intracellular enzyme | 2012 |
| JAK1, JAK2 | Baricitinib | Intracellular enzyme | 2018 |
| JAK1 | Filgotinib | Intracellular enzyme | – |
| JAK1 | Upadacitinib | Intracellular enzyme | 2019 |
Note: Approval date refers to the time when the RA indication is approved.